摘要
目的探讨依达拉奉联合血栓通对急性脑梗死患者血清超敏C反应蛋白(hs-CRP)和可溶性细胞间黏附分子-1(sICAM)的影响。方法 84例急性脑梗死患者随机分为两组,对照组40例,治疗组44例。对照组采用常规治疗,治疗组在常规治疗的基础上加用依达拉奉和血栓通,共治疗21d。治疗后评价疗效和测定血清hs-CRP和sICAM。结果对照组总有效率72.5%,治疗组总有效率为88.6%,两组差异有统计学意义(P<0.05)。两组在治疗后hs-CRP和sICAM均明显降低,但治疗组降低更明显(P<0.05)。结论依达拉奉联合血栓通可以减少急性脑梗死患者血清hs-CRP和sICAM的表达,从而治疗疾病。
Objective To study Edaravone plus xueshuantong on the high sensivitity C-reactive protein（hs-CRP） and soluble intercellular adhesion molecule（sICAM） in the serum in the patients with acute cerebral infarction.Methods Eighty-four patients with acute cerebral infarction were randomly divided into two groups,the control treatment（n=40 cases） and the treatment group（n=44 cases）.The patients in the control group were treated through conventional treatment and the patients in the treatment group were treated through Edaravone plus xueshuantong.They were treated for twenty-one days.The hs-CRP and sICAM were detected before and after treatment.Results The total effective rates were 72.5% in the control group and 88.6% in the treatment group.There was a significant different（P〈0.05）.The hs-CRP and sICAM were decreased after treatment.Conclusion Edaravone plus Xueshuantong can decreased the hs-CRP and sICAM,which can improve acute cerebral infarction.
出处
《中国实用医药》
2012年第19期16-18,共3页
China Practical Medicine
